Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway

Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway

Multiple myeloma (MM) is a malignant plasma cell disease. The activity of PIK3CG (PI3K catalytic subunit γ) is regulated directly by G-protein-coupled receptor and has been confirmed to be highly expressed in MM cells. This study aimed to determine the effect of pharmacological inhibition of PIK3CG...

Full description

Bibliographic Details
Main Authors:	Xiaotang Di, Yiwen Pan, Jinhua Yan, Jing Liu, Doudou Wen, Hao Jiang, Shubing Zhang
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	Heliyon
Subjects:	Multiple myeloma PIK3CG c-Myc Melphalan Targeted therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844023103732

Similar Items

Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer [Corrigendum]
by: Chang J, et al.
Published: (2020-05-01)

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
by: Morabito F, et al.
Published: (2021-07-01)

Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment
by: Su-Hee Cho, et al.
Published: (2019-05-01)

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma
by: Arianna Giacomini, et al.
Published: (2024-11-01)

FGF signaling inhibits the proliferation of human myeloma cells and reduces c-<it>myc </it>expression
by: Bush Andrew B, et al.
Published: (2003-12-01)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
by: Se Ryeon Lee, et al.
Published: (2019-11-01)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
by: Taleb Azarm, et al.
Published: (2012-01-01)

Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)
by: Ga-Young Song, et al.
Published: (2022-08-01)

Identification of PIK3CG as a hub in septic myocardial injury using network pharmacology and weighted gene co‐expression network analysis
by: Qiong Liu, et al.
Published: (2023-01-01)

Myc rearrangement redefines the stratification of high‐risk multiple myeloma
by: Xianghong Jin, et al.
Published: (2024-06-01)

Anaplastic multiple myeloma with MYC rearrangement
by: Satoshi Ichikawa, et al.
Published: (2022-01-01)

Design, synthesis, and activity evaluation of 2-iminobenzimidazoles as c-Myc inhibitors for treating multiple myeloma
by: Shihao Li, et al.
Published: (2024-04-01)

Correlation between Melphalan chemotherapy with longitudinal global strain indices of the left ventricle in multiple myeloma patients: a velocity vector imaging (VVI) echocardiography study
by: Liaosadat Mirsafaee, et al.
Published: (2024-01-01)

Autopsy analysis may contribute to establish actual incidence of second primary malignancies in myeloma
by: Junichiro Takano, et al.
Published: (2015-12-01)

Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment
by: Min Ji Jeon, et al.
Published: (2024-11-01)

1,2,3,4,6-Penta-O-Galloyl-Beta-D-Glucopyranoside Inhibits Proliferation of Multiple Myeloma Cells Accompanied with Suppression of MYC Expression
by: Duurenjargal Tseeleesuren, et al.
Published: (2018-02-01)

Small Molecule 20S Proteasome Enhancer Regulates MYC Protein Stability and Exhibits Antitumor Activity in Multiple Myeloma
by: Evert Njomen, et al.
Published: (2022-04-01)

A case report: high dose melphalan as a conditioning regimen for multiple myeloma induces sinus arrest
by: Liang-Liang Ma, et al.
Published: (2020-03-01)

Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation
by: Gabriele Buda, et al.
Published: (2021-08-01)

Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
by: Ruosi Yao, et al.
Published: (2022-05-01)

Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities
by: Catriona Elizabeth Mactier, et al.
Published: (2012-10-01)

Therapy-related B-lymphoblastic leukemia after multiple myeloma
by: Michael E. Kallen, et al.
Published: (2022-01-01)

Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma
by: Yao R, et al.
Published: (2020-09-01)

Impact of melphalan day -1 vs day -2 on outcomes after autologous stem cell transplant for multiple myeloma
by: Aimee Merino, et al.
Published: (2024-03-01)

Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis
by: Fei Gao, et al.
Published: (2021-11-01)

Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYC
by: Rachel E. Piddock, et al.
Published: (2018-05-01)

Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation
by: Amalia Domingo-González, et al.
Published: (2024-09-01)

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
by: Andrew R Conery, et al.
Published: (2016-01-01)

Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India
by: Nithin Sashidharan, et al.
Published: (2015-05-01)

Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen
by: Arjen Gebraad, et al.
Published: (2022-05-01)

Targeting c-Myc Unbalances UPR towards Cell Death and Impairs DDR in Lymphoma and Multiple Myeloma Cells
by: Andrea Arena, et al.
Published: (2022-03-01)

Views on the Current Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum
by: SUN Liying, et al.
Published: (2023-10-01)

Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice
by: Lei Wang, et al.
Published: (2019-07-01)

Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma
by: Giulio Donati, et al.
Published: (2023-05-01)

Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma
by: Hong Phuong Nguyen, et al.
Published: (2023-08-01)

The TT Genotype of the <i>KIAA1524 rs2278911</i> Polymorphism Is Associated with Poor Prognosis in Multiple Myeloma
by: Aneta Szudy-Szczyrek, et al.
Published: (2023-03-01)

Corrigendum: Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma
by: Hong Phuong Nguyen, et al.
Published: (2023-11-01)

Disrupted care for multiple myeloma in an amenorrheic woman due to a false-positive pregnancy test: A case report
by: Kaley Parchinski, et al.
Published: (2024-09-01)

Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma
by: Angélique Bruyer, et al.
Published: (2023-12-01)

Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions
by: Nwabuko OC, et al.
Published: (2017-05-01)